Early discontinuation of endocrine therapy for breast cancer: Who is at risk in clinical practice?
Purpose: Despite evidence supporting at least five years of endocrine therapy for early breast cancer, many women discontinue therapy early. We investigated the impact of initial therapy type and specific comorbidities on discontinuation of endocrine therapy in clinical practice. Methods: We identif...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
SpringerOpen
2014
|
| Online Access: | http://hdl.handle.net/20.500.11937/55821 |